VASP Phosphorylation and Asthma
Author Information
Author(s): Annette T Hastie, Min Wu, Gayle C Foster, Gregory A Hawkins, Vikas Batra, Katherine A Rybinski, Rosemary Cirelli, James G Zangrilli, Stephen P Peters
Primary Institution: Wake Forest University School of Medicine
Hypothesis
Inhalation of the β-agonist albuterol increases VASP phosphorylation in asthmatic epithelium, altering cell adhesion.
Conclusion
Decreased VASP phosphorylation was observed in epithelial cells of asthmatics compared to nonasthmatic normals, despite response to β-agonist.
Supporting Evidence
- VASP phosphorylation increased after allergen challenge but was not significantly greater in asthmatics.
- Regularly inhaled albuterol significantly increased VASP phosphorylation in asthmatic subjects.
- Asthmatic epithelial cells had a significantly lower ratio of phosphorylated to unphosphorylated VASP compared to normals.
Takeaway
Asthmatics have less of a protein called VASP that helps their lung cells stick together and heal, even when they use asthma medicine.
Methodology
Bronchial epithelium was obtained from asthmatic and non-asthmatic subjects before and after allergen challenge and β2-agonist use, with VASP phosphorylation examined in Western blots.
Potential Biases
Potential bias in subject selection and response to β2-agonist treatment.
Limitations
The study may not account for all genetic variations affecting VASP phosphorylation.
Participant Demographics
31 allergic asthmatics and 17 nonasthmatic normals, with a mean age of 29.6 years for asthmatics and 27.1 years for normals.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website